- Home
- KNOP vs ALDX Comparison
KNOP vs ALDX Comparison
Compare KNOP & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- ALDX
- Stock Information
- Founded
- KNOP 2013
- ALDX 2004
- Country
- KNOP United Kingdom
- ALDX United States
- Employees
- KNOP N/A
- ALDX N/A
- Industry
- KNOP Marine Transportation
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- KNOP Consumer Discretionary
- ALDX Health Care
- Exchange
- KNOP Nasdaq
- ALDX Nasdaq
- Market Cap
- KNOP 316.9M
- ALDX 314.6M
- IPO Year
- KNOP 2013
- ALDX 2014
- Fundamental
- Price
- KNOP $9.02
- ALDX $5.07
- Analyst Decision
- KNOP
- ALDX Strong Buy
- Analyst Count
- KNOP 0
- ALDX 2
- Target Price
- KNOP N/A
- ALDX $9.50
- AVG Volume (30 Days)
- KNOP 85.3K
- ALDX 679.8K
- Earning Date
- KNOP 12-03-2025
- ALDX 11-06-2025
- Dividend Yield
- KNOP 1.15%
- ALDX N/A
- EPS Growth
- KNOP N/A
- ALDX N/A
- EPS
- KNOP 0.69
- ALDX N/A
- Revenue
- KNOP $332,137,000.00
- ALDX N/A
- Revenue This Year
- KNOP $11.88
- ALDX N/A
- Revenue Next Year
- KNOP $2.04
- ALDX $63.48
- P/E Ratio
- KNOP $13.06
- ALDX N/A
- Revenue Growth
- KNOP 12.14
- ALDX N/A
- 52 Week Low
- KNOP $5.28
- ALDX $1.14
- 52 Week High
- KNOP $9.93
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- KNOP 54.37
- ALDX 43.30
- Support Level
- KNOP $8.71
- ALDX $4.70
- Resistance Level
- KNOP $9.44
- ALDX $5.40
- Average True Range (ATR)
- KNOP 0.31
- ALDX 0.28
- MACD
- KNOP -0.01
- ALDX -0.04
- Stochastic Oscillator
- KNOP 64.71
- ALDX 34.19
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.